John J. Schembri
Comptroller/Controller/Auditor chez AKERO THERAPEUTICS, INC.
Profil
John J.
Schembri is currently the Vice President-Finance & Controller at Akero Therapeutics, Inc. He previously worked as a Finance Director & Controller at Cell Genesys, Inc. and COR Therapeutics, Inc. He also held the position of Principal at The Clorox Co. Additionally, he served as Vice President & Controller at Sirna Therapeutics, Inc. and as Chief Financial Officer at BiPar Sciences, Inc. He was also the Secretary, Vice President-Finance & Administration at Global Blood Therapeutics, Inc. and the Chief Financial Officer & Vice President at StemPar Sciences, Inc. Schembri received his undergraduate degree from California Polytechnic State University (San Luis Obispo).
Postes actifs de John J. Schembri
| Sociétés | Poste | Début |
|---|---|---|
| AKERO THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 01/01/2019 |
Anciens postes connus de John J. Schembri
| Sociétés | Poste | Fin |
|---|---|---|
Sirna Therapeutics, Inc.
 Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | Comptroller/Controller/Auditor | 17/05/2007 |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Director of Finance/CFO | 01/01/2006 |
COR Therapeutics, Inc.
 COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Director of Finance/CFO | 01/01/2002 |
Telik, Inc.
 Telik, Inc. Pharmaceuticals: MajorHealth Technology Telik, Inc. is an innovative biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. Its TELINTRA product is used for treatment of cytopenias due to myelodysplastic syndrome and chemotherapy. The company's product candidates were discovered using its proprietary drug discovery technology TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Telik was founded in September 1988 and is headquartered in Palo Alto, CA. | Director of Finance/CFO | - |
| THE CLOROX COMPANY | Corporate Officer/Principal | - |
Formation de John J. Schembri
| California Polytechnic State University (San Luis Obispo) | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| THE CLOROX COMPANY | Consumer Non-Durables |
| AKERO THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Health Technology |
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | Commercial Services |
Telik, Inc.
Telik, Inc. Pharmaceuticals: MajorHealth Technology Telik, Inc. is an innovative biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. Its TELINTRA product is used for treatment of cytopenias due to myelodysplastic syndrome and chemotherapy. The company's product candidates were discovered using its proprietary drug discovery technology TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Telik was founded in September 1988 and is headquartered in Palo Alto, CA. | Health Technology |
BiPar Sciences, Inc.
 BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ. | Health Technology |
StemPar Sciences, Inc.
 StemPar Sciences, Inc. Medical/Nursing ServicesHealth Services StemPar Sciences, Inc. develops cancer drugs treatments. It provides cancer drugs that attack solid tumors by simultaneously disrupting their source of energy and their ability to repair chemotherapy/radiation induced DNA damage. The company was founded by Hoyoung Huh and Mircea Florin Mihaescu in 2012 and is headquartered in Mill Valley, CA. | Health Services |
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |
